


See “Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study” on page 223.



Supplementary Fig. 3. Comparison of number of patients with loss of response (LOR) between antibodies to infliximab (ATI) positive, ATI negative and ATI inconclusive groups (Study 1). This is a graph of ATI assessed using assay A. No statistically significant in frequency of LOR was seen in 3 groups various ATI conditions ($P=0.0676$).